Abstract
The success of tumor immunotherapy targeting the inhibitory co-receptors PD-1 and CTLA-4 has indicated that many other co-receptors might be potential druggable targets, despite limited information about their functional differences. Here we identified a unique target selectivity for the inhibitory co-receptor LAG-3 that was intrinsic to its immunoregulatory roles. Although LAG-3 has been reported to recognize major histocompatibility complex (MHC) class II, it did not recognize MHC class II universally; instead, we found that it selectively recognized stable complexes of peptide and MHC class II (pMHCII). LAG-3 did not directly interfere with interactions between the co-receptor CD4 and MHC class II or between the T cell antigen receptor and MHC class II. Instead, LAG-3 preferentially suppressed T cells responsive to stable pMHCII by transducing inhibitory signals via its intracellular region. Thus, LAG-3 might function more selectively than previously thought and thereby maintain tolerance to dominant autoantigens.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 270, 985–988 (1995).
Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547 (1995).
Nishimura, H. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 291, 319–322 (2001).
Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999).
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. & Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212–1218 (2013).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Triebel, F. et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393–1405 (1990).
Okazaki, T. et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J. Exp. Med. 208, 395–407 (2011).
Bettini, M. et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J. Immunol. 187, 3493–3498 (2011).
Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).
Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875–7880 (2010).
Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37 (2009).
Butler, N. S. et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13, 188–195 (2012).
Andrews, L. P., Marciscano, A. E., Drake, C. G. & Vignali, D. A. A. LAG3 (CD223) as a cancer immunotherapy target. Immunol. Rev. 276, 80–96 (2017).
Workman, C. J., Rice, D. S., Dugger, K. J., Kurschner, C. & Vignali, D. A. A. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur. J. Immunol. 32, 2255–2263 (2002).
Huard, B., Prigent, P., Tournier, M., Bruniquel, D. & Triebel, F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 25, 2718–2721 (1995).
Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823–836 (2011).
Sadegh-Nasseri, S. et al. Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol. Res. 47, 56–64 (2010).
Peterson, Da, DiPaolo, R. J., Kanagawa, O. & Unanue, E. R. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 11, 453–462 (1999).
Lovitch, S. B., Walters, J. J., Gross, M. L. & Unanue, E. R. APCs present Aβk-derived peptides that are autoantigenic to type B T cells. J. Immunol. 170, 4155–4160 (2003).
Terskikh, A. V. et al. ‘Peptabody’: a new type of high avidity binding protein. Proc. Natl Acad. Sci. USA 94, 1663–1668 (1997).
Chang, C. H. & Flavell, R. A. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. 181, 765–767 (1995).
Kozono, H., White, J., Clements, J., Marrack, P. & Kappler, J. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 369, 151–154 (1994).
Ford, M. L. & Evavold, B. D. Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. J. Immunol. 171, 1247–1254 (2003).
Lazarski, C. A. et al. The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 23, 29–40 (2005).
Stadinski, B. D. et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11, 225–231 (2010).
Udyavar, A., Alli, R., Nguyen, P., Baker, L. & Geiger, T. L. Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity. J. Immunol. 182, 4439–4447 (2009).
Alli, R., Nguyen, P. & Geiger, T. L. Altered differentiation, diminished pathogenicity, and regulatory activity of myelin-specific T cells expressing an enhanced affinity TCR. J. Immunol. 187, 5521–5531 (2011).
Baumgartner, C. K., Ferrante, A., Nagaoka, M., Gorski, J. & Malherbe, L. P. Peptide–MHC class II complex stability governs CD4 T cell clonal selection. J. Immunol. 184, 573–581 (2010).
Wolf, P. R. et al. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur. J. Immunol. 28, 2605–2618 (1998).
Bikoff, E. K., Germain, R. N. & Robertson, E. J. Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity 2, 301–310 (1995).
Carrasco-Marin, E., Shimizu, J., Kanagawa, O. & Unanue, E. R. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J. Immunol. 156, 450–458 (1996).
Daniel, D. & Wegmann, D. R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl Acad. Sci. USA 93, 956–960 (1996).
Mohan, J. F., Petzold, S. J. & Unanue, E. R. Register shifting of an insulin peptide–MHC complex allows diabetogenic T cells to escape thymic deletion. J. Exp. Med. 208, 2375–2383 (2011).
Levisetti, M. G., Suri, A., Petzold, S. J. & Unanue, E. R. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J. Immunol. 178, 6051–6057 (2007).
Acha-Orbea, H. & Mc Devitt, H. O. The first external domain of the nonobese diabetic mouse class II I-Ab chain is unique. Proc. Natl Acad. Sci. USA 84, 2435–2439 (1987).
Gardiner, A., Richards, K. A., Sant, A. J. & Arneson, L. S. Conformation of MHC class II I-Ag7 is sensitive to the P9 anchor amino acid in bound peptide. Int. Immunol. 19, 1103–1113 (2007).
Suri, A. et al. In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket. J. Immunol. 168, 1235–1243 (2002).
Mohan, J. et al. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat. Immunol. 11, 350–354 (2010).
Wang, X. X. et al. Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4–HLA-DR1 complex. Proc. Natl Acad. Sci. USA 108, 15960–15965 (2011).
Workman, C. J., Dugger, K. J. & Vignali, D. A. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J. Immunol. 169, 5392–5395 (2002).
Baixeras, E. et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176, 327–337 (1992).
Grosso, J. F. et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine selfand tumor-tolerance systems. J. Clin. Invest. 117, 3383–3392 (2007).
Workman, C. J. & Vignali, D. A. A. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J. Immunol. 174, 688–695 (2005).
Li, W., Joshi, M., Singhania, S., Ramsey, K. & Murthy, A. Peptide vaccine: progress and challenges. Vaccines 2, 515–536 (2014).
White, J. et al. Two better cell lines for making hybridomas expressing specific T cell receptors. J. Immunol. 143, 1822–1825 (1989).
Mizushima, S. & Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18, 5322 (1990).
Gregori, S., Giarratana, N., Smiroldo, S. & Adorini, L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171, 4040–4047 (2003).
Acknowledgements
We thank H. Kozono and O. Kanagawa for critical reading of the manuscript; L. Ignatowicz, M. Hattori, T. Kurosaki, and T. Kitamura for kindly providing BW-1100.129.237, CH27, IIA1.6, and Plat-E cells, respectively; T. Honjo for kindly providing DO11.10, 2B4.11, WEHI-231, P815, and SP2/o cells; K. Murphy for kindly providing DO11.10 Tg mice; A. Otsuka, Y. Okamoto, M. Aoki, and H. Tsuduki for technical assistance; and the other members of our laboratory for helpful discussions. This work was supported in part by the Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency, Basic Science and Platform Technology Program for Innovative Biological Medicine of the Japan Agency for Medical Research and Development (JP18am0301007), Grant-in-Aid by the Japan Society for the Promotion of Science (JP18H05417), the Tokyo Biochemical Research Foundation, and Uehara Memorial Foundation.
Author information
Authors and Affiliations
Contributions
T.M., I.O., and T.O. designed and analyzed the experiments. T.M., I.O., S.T., D.S., T.K.M., and K.S. performed experiments. T.M., I.O., D.S., T.K.M., and K.S. performed the staining and functional experiments using cultured cells. T.M. and S.T. generated gene-targeted cells. T.M. performed the staining experiments of primary cells and functional experiments using NOD mice. I.O. performed the expression cloning. T.M. and T.O. wrote the manuscript with all authors contributing to writing. T.O. oversaw the entire project.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Integrated supplementary information
Supplementary Figure 1 Mouse LAG-3-P111A mutant lacking inhibitory and binding capacities.
a, Amino acid sequence alignment of the mouse and human LAG-3 D1 domain. Residues substituted with alanine and proline 111 are indicated in blue and red, respectively. b,c, Inhibitory function of mouse LAG-3 mutants. DO11.10 T cells expressing EGFP (Mock), mLAG-3-WT, or mLAG-3 mutants with alanine substitution were stimulated with IIA1.6 cells pulsed with OVA323–339 peptide in the presence or absence of anti-LAG-3 blocking Ab (TKB58) and the concentration of IL-2 in the culture supernatant was measured by ELISA (b). Percent inhibition of IL-2 production by mouse LAG-3-WT and -mutants is shown (c). d, Comparable surface expression levels of LAG-3 and LAG-3-P111A. EGFP (Mock), LAG-3, and LAG-3-P111A were retrovirally transduced into DO11.10 T cells and the surface expression levels were determined by flow cytometric analysis using anti-LAG-3 Abs specific to D1 domain (TKB58) and D2 domain (C9B7W). e, Disappearance of the binding capacity of LAG-3-EC to IIA1.6 cells by P111A substitution. Binding intensities of pentameric LAG-3-EC and LAG-3-P111A-EC to IIA1.6 cells were determined by flow cytometric analysis. Bar graphs indicate the mean of technical duplicates in one representative experiment (b,c). Gray shaded histogram represents the negative control stained with the secondary Ab (e). Data are representative of two (b,c), or more than three independent experiments (d,e).
Supplementary Figure 2 Gating strategy for mouse primary B cells and DCs in flow cytometric analysis.
Bone marrow cells and splenocytes were stained with the indicated Abs to be divided into indicated subpopulations. MHCII was detected by M5/114.15.2 that does not affect the LAG-3-EC binding to cells at the working concentration for flow cytometry (0.07 μg/ml). MZ, marginal zone B cell; MZP, marginal zone precursor B cell; FOL I, follicular type I B cell; FOL II, follicular type II B cell; pDC, plasmacytoid dendritic cell; cDC, conventional dendritic cell. Data are representative of three independent experiments.
Supplementary Figure 3 Conferment of the capacity to exert LAG-3 inhibitory function on BW5147 cells by CIITA.
a, LAG-3-EC binding intensities and MHCII expression levels of BW5147-I-Ad cells with or without retroviral transduction of CIITA. Overexpression of CIITA conferred the LAG-3 binding capacity to BW5147-I-Ad cells as well as induced the expression of endogenous I-Ak and I-Ek. b,c, Exertion of LAG-3 inhibitory function by BW5147-I-Ad cells overexpressing CIITA. DO11.10 T cells expressing EGFP (Mock) or LAG-3 were stimulated with indicated cells pulsed with indicated amount of OVA323−339 peptide. IL-2 concentration (b) and LAG-3-mediated inhibitory effect (c) are shown. d, Requirement of I-Ak or I-Ek for the LAG-3-EC binding to BW5147-CIITA cells. LAG-3-EC binding intensities and MHCII expression levels of BW5147-CIITA cells lacking I-Ak and I-Ek generated by using CRISPR/Cas9 system. Each symbol represents an individual technical replicate (c, n = 4). Bar graphs indicate the mean of technical duplicates in one representative experiment (b) or the mean ± s.d. of technical quadruplicates pooled from two independent experiments (c). ND, not detected. Two-tailed paired Student’s t-test (d,f). ***P < 0.005. Data are representative of more than three independent experiments (a,b,d).
Supplementary Figure 4 Induction of Ii and H2-DM by CIITA, expression of Ii and H2-DM on LAG-3-binding cells, and lack of Ii and H2-DM expression in cells with genetic deletion of the corresponding gene.
a, Gene expression of MHCII accessory molecules in P815-CIITA and IIA1.6 cells relative to parental P815 cells analyzed by qPCR. Values were normalized to the expression of Actb. b, Reduced and completely abolished expression of Ii and H2-DM, respectively in IIA1.6-CIITA KO cells. Intracellular expression of Ii and H2-DM in IIA1.6-CIITA KO cells was determined by flow cytometric analysis. c, Lower expression of Ii and H2-DM in LAG-3-EC-low/negative cell populations compared with LAG-3-EC-high populations shown in Fig. 1b. Relative expression levels (geoMFI) of Ii, H2-DM and MHCII in bone marrow (BM) mature B cells and spleen MZP B cells (left), and LAG-3-EC-low/negative and -high populations in spleen CD8+ cDCs (right) were determined by flow cytometric analysis. d, The defective expression of Ii and H2-DM on IIA1.6 cells in which genes encoding Ii and H2-DMα, respectively were knocked-out by using CRISPR/Cas9 system. Each symbol represents an individual mouse (c). Bar graphs indicate the mean of technical triplicates in one representative experiment (a) or the mean ± s.e.m. of 3 mice in one representative experiment (c). Two-tailed Mann-Whitney U-test (c). *P < 0.05, ***P < 0.005. Data are representative of two (a,c) or three (b,d) independent experiments.
Supplementary Figure 5 Accumulation of LAG-3 at the interface between T cells and APCs expressing stable but not unstable pMHCII.
a–e, Confocal microscopy of LAG-3-EGFP and LAG-3-P111A-EGFP on DO11.10 T cells co-cultured with indicated cell lines expressing endogenous or exogenous I-Ad (a), expressing CIITA (b), expressing exogenous I-Ad and non-cognate stable or unstable pMHCII (c–e) pulsed with OVA323−339 peptide. Scale bars, 10 μm. Images are representative of more than two independent experiments (a–e). White arrowheads indicate the accumulation of LAG-3-EGFP at the interface of T cells and APCs.
Supplementary Figure 6 Dose-dependent binding and low dissociation rate of pentameric human LAG-3-EC and human CD4-EC.
a,b, LAG-3-EC binding intensities and MHCII expression levels of Jurkat cells with or without retroviral transduction of human CIITA (a) and BW5147 cells expressing HLA-DR1 covalently linked with pHA307–318 (b). Overexpression of human CIITA induced the expression of endogenous HLA-DR and HLR-DQ in Jurkat cells and conferred the LAG-3 binding capacity. Expression of HLA-DR1 covalently linked with dominant epitope of influenza HA (pHA307–318) conferred the LAG-3 binding capacity to BW5147 cells. c,d, Dose-dependent binding of hLAG-3-EC and hCD4-EC to Raji and Jurkat-hCIITA cells. Raji and Jurkat-hCIITA cells were incubated with hLAG-3-EC (WT) and hLAG-3-P115A-EC (P115A) (c) or hCD4-EC (d) at indicated concentrations, and their bindng was detected by streptavidin or anti-DYKDDDDK Tag Ab, respectively. The biniding intensities (geoMFI) of solublue proteines were determined by flow cytometric analysis. The dose-dependent binding curves were obtained by fitting the data to the Hill equation. The bindings of hLAG-3-EC and hCD4-EC to Raji and Jurkat-hCIITA cells were saturated at 20 and 5 μg/ml, respectively. e, Slow disscociation rate of hLAG-3-EC and hCD4-EC from Jurkat-hCIITA cells. Jurkat-hCIITA cells were incubated with hLAG-3-EC or hCD4-EC at saturating concentrations, follwed by the staining with streptavidin or anti-DYKDDDDK Ab, respectively. The biniding intensities (geoMFI) of solublue proteines after the subsequent incubation for the indicated time period were determined by flow cytometric analysis. The percentage of binding (Log10 geoMFI) was calculated relative to the binding at 0 min. Data are representative of two independent experiments (a–e).
Supplementary Figure 7 CD4 dependency of DO11.10, 2B4.11, and BWCD4-3A9 TCR cells for activation.
a, Surface expression levels of endogenous or exogenous CD4 on the indicated cell lines. b, CD4-dependent IL-2 production of BWCD4-3A9 TCR cells. Indicated cell lines were stimulated with indicated cells pulsed with the indicated amount of antigenic peptides in the presence of rat IgG2b isotype control (RTK4530) or anti-CD4 blocking Ab (GK1.5), and the concentration of IL-2 in the culture supernatant was measured by ELISA. Bar graphs indicate the mean of technical duplicates in one representative experiment. c, Comparable surface expression levels of LAG-3 and its mutant lacking the intracellular region (ΔIC). LAG-3 and LAG-3-ΔIC were overexpressed in indicated cell lines under the control of chicken beta-actin promoter and LTR retroviral promoter, respectively. ND, not detected. Data are representative of more than two independent experiments (a–c).
Supplementary Figure 8 Schematic representations of the LAG-3-mediated inhibition of T cell activation at peptide- and APC-type-specific levels and the inhibitory mechanism of LAG-3.
a, LAG-3 strongly inhibits the activation of T cells recognizing stable pMHCII by binding to stable pMHCII (left). LAG-3 can also partially inhibit the activation of T cells recognizing unstable pMHCII and pMHCI, when APCs express stable non-cognate pMHCII abundantly (right). b, Current findings indicate that LAG-3 inhibits T cell activation by transducing inhibitory signal via its intracellular region (left) but not by attenuating the CD4-MHCII (middle) or the TCR-pMHCII (right) interactions.
Electronic supplementary material
Supplementary Text and Figures
Supplementary Figures 1–8
Rights and permissions
About this article
Cite this article
Maruhashi, T., Okazaki, Im., Sugiura, D. et al. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol 19, 1415–1426 (2018). https://doi.org/10.1038/s41590-018-0217-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-018-0217-9
This article is cited by
-
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies
Stem Cell Research & Therapy (2024)
-
A novel ferroptosis-related gene signature for overall survival prediction in patients with gastric cancer
Scientific Reports (2024)
-
Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab
Nature Communications (2024)
-
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Signal Transduction and Targeted Therapy (2024)
-
Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Nature Cancer (2024)